Assumptions Based on Clinically Low Risk Features May Lead to Potential Undertreatment

Dr. Rena Callahan highlights the limitations of clinical features to predict benefit from extended endocrine therapy, potentially resulting in undertreatment for women with early-stage, HR+ breast cancer.
Watch the full product theater recording from 2023 San Antonio Breast Cancer Symposium (SABCS): www.hologic.co...
For intended use and limitations, visit breastcancerindex.com. Dr. Rena Callahan is a consultant for Biotheranostics, Inc. Statements reflect the speaker’s own personal views and interpretations.